These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37611117)

  • 1. Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease.
    Long MD; Parlett L; Lewis JD; Haynes K; Adimadhyam S; Hou L; Wolfe A; Toh S; Burris J; Dorand J; Kappelman MD
    Inflamm Bowel Dis; 2024 Aug; 30(8):1345-1352. PubMed ID: 37611117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
    Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
    Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Hospital-related Outcomes of COVID-19 Infection in Patients With Inflammatory Bowel Disease in the Early Pandemic Phase: A Nationwide Inpatient Database Survey.
    Naseem K; Sohail A; Quang Nguyen V; Khan A; Cooper G; Lashner B; Katz J; Cominelli F; Regueiro M; Mansoor E
    Inflamm Bowel Dis; 2024 Aug; 30(8):1334-1344. PubMed ID: 37725039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.
    Creemers RH; Rezazadeh Ardabili A; Jonkers DM; Leers MPG; Romberg-Camps MJ; Pierik MJ; van Bodegraven AA
    PLoS One; 2021; 16(10):e0258271. PubMed ID: 34610041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Tripathi K; Godoy Brewer G; Thu Nguyen M; Singh Y; Saleh Ismail M; Sauk JS; Parian AM; Limketkai BN
    Inflamm Bowel Dis; 2022 Aug; 28(8):1265-1279. PubMed ID: 34718595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
    Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
    JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association of Medications and Vaccination with Risk of Pneumonia in Inflammatory Bowel Disease.
    Gregory MH; Ciorba MA; Wiitala WL; Stidham RW; Higgins P; Morley SC; Hou JK; Feagins LA; Govani SM; Cohen-Mekelburg SA; Waljee AK
    Inflamm Bowel Dis; 2020 May; 26(6):919-925. PubMed ID: 31504531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of pneumonia among patients with inflammatory bowel disease.
    Long MD; Martin C; Sandler RS; Kappelman MD
    Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor Necrosis Factor-α Therapy Is Associated With Reduced Risk of Thromboembolic Events in Hospitalized Patients With Inflammatory Bowel Disease.
    deFonseka AM; Tuskey A; Conaway MR; Behm BW
    J Clin Gastroenterol; 2016 Aug; 50(7):578-83. PubMed ID: 26368297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
    Lewis JD; Scott FI; Brensinger CM; Roy JA; Osterman MT; Mamtani R; Bewtra M; Chen L; Yun H; Xie F; Curtis JR
    Am J Gastroenterol; 2018 Mar; 113(3):405-417. PubMed ID: 29336432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
    Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Hong SN; Kim HJ; Kim KH; Han SJ; Ahn IM; Ahn HS
    Aliment Pharmacol Ther; 2017 Jan; 45(2):253-263. PubMed ID: 27933686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease.
    Sahyoun LC; Fetene J; McMillan C; Protiva P; Al Bawardy B; Gaidos JKJ; Proctor D
    Dig Dis Sci; 2024 May; 69(5):1654-1660. PubMed ID: 38466459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation.
    Lev-Tzion R; Focht G; Lujan R; Mendelovici A; Friss C; Greenfeld S; Kariv R; Ben-Tov A; Matz E; Nevo D; Barak-Corren Y; Dotan I; Turner D
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):e1263-e1282. PubMed ID: 34954338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
    Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
    Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.